OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

Bibliography

• Wender PH. Attention deficit hyperactivity disorder in adults. Oxford University Press, Oxford; 1995
   Google Scholar
• McBurnett K, Pfiffner LJ, Willcutt E, Experimental cross-validation of DSM-IV types of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 1999;38:17-24
   Google Scholar
• Lahey BB, Applegate B, McBurnett K, DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994;151:1673-85
   PubMed Web of Science ®Google Scholar
• Hart EL, Lahey BB, Loeber R, Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995;23:729-49
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Press, Inc., Washington, DC; 2000
   Google Scholar
• Faraone SV, Upadhyaya HP. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry 2007;68:e28
   PubMedGoogle Scholar
• Applegate B, Lahey BB, Hart EL, Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry 1997;36:1211-21
   PubMed Web of Science ®Google Scholar
• Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1204-10
   PubMed Web of Science ®Google Scholar
• Rohde LA, Biederman J, Zimmermann H, Exploring ADHD age-of-onset criterion in Brazilian adolescents. Eur Child Adolesc Psychiatry 2000;9:212-18
   PubMedGoogle Scholar
• Faraone SV, Antshel KM. Diagnosing and treating attention-deficit/hyperactivity disorder in adults. World Psychiatry 2008;7:131-6
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Simon V, Czobor P, Balint S, Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194:204-11
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386-92
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder – United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54:842-7
   PubMedGoogle Scholar
• Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192-202
   PubMed Web of Science ®Google Scholar
• Halmoy A, Fasmer OB, Gillberg C, Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord 2009;13:175-87
   PubMed Web of Science ®Google Scholar
• Sobanski E, Bruggemann D, Alm B, Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257:371-7
   PubMed Web of Science ®Google Scholar
• Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: a guide to current theory, diagnosis, and treatment. Johns Hopkins University Press, Baltimore, MD; 1999
   Google Scholar
• Thompson AL, Molina BS, Pelham W Jr, Gnagy EM. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol 2007;32:745-59
   PubMed Web of Science ®Google Scholar
• Molina BS, Pelham WE, Gnagy EM, Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. Alcohol Clin Exp Res 2007;31:643-54
   PubMed Web of Science ®Google Scholar
• Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev 2007;39:94-105
   PubMed Web of Science ®Google Scholar
• Wilens TE, Prince J, Biederman J. ADHD in adults. In: McBurnett K, Pfiffner LJ, editors. Attention deficit hyperactivity disorder: concepts, controversies, new directions.: Informa Healthcare, New York; 2008. p. 273-90
   Google Scholar
• Biederman J, Monuteaux MC, Mick E, Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty CR, Monuteaux MC, Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 2010;167:409-17
   PubMed Web of Science ®Google Scholar
• AACAP. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:85-121S
   PubMedGoogle Scholar
• American Academy of Pediatrics; Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44
   PubMed Web of Science ®Google Scholar
• Blondis TA, Brown KA. The American academy of pediatrics ADHD practice guidelines: a critique. In: McBurnett K, Pfiffner LJ, editors, Attention deficit hyperactivity disorder: concepts, controversies, new directions. Informa Healthcare, New York; 2008. p. 331-9
   Google Scholar
• Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatr Clin North Am 2010;33:497-509
   PubMed Web of Science ®Google Scholar
• Solanto MV, Marks DJ, Wasserstein J, Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 2010;167:958-68
   Google Scholar
• Young S, Amarasinghe JM. Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry 2010;51:116-33
   PubMed Web of Science ®Google Scholar
• Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:24-9
   PubMed Web of Science ®Google Scholar
• Koesters M, Becker T, Kilian R, Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009;23:733-44
   PubMed Web of Science ®Google Scholar
• Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD, Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Faries DE, Moore RJ, Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008;95:140-6
   PubMed Web of Science ®Google Scholar
• Michelson D, Read HA, Ruff DD, CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242-51
   PubMed Web of Science ®Google Scholar
• ter Laak MA, Temmink AH, Koeken A, Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr Neurol 2010;43:159-62
   PubMedGoogle Scholar
• Pohl GM, Van Brunt DL, Ye W, A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 2009;9:95
   PubMed Web of Science ®Google Scholar
• McNeil Pediatrics Division of Ortho-McNeil–Janssen Pharmaceuticals, Inc. Summary of Full Prescribing Information, 2010
   Google Scholar
• Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A, Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11
   PubMed Web of Science ®Google Scholar
• Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006;7:2119-38
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992;15:191-222
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2000;21:RC121
   Google Scholar
• Krause KH, Dresel SH, Krause J, Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285:107-10
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52
   PubMed Web of Science ®Google Scholar
• Kim BN, Lee JS, Cho SC, Lee DS. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. Yonsei Med J 2001;42:19-29
   PubMed Web of Science ®Google Scholar
• Szobot CM, Ketzer C, Cunha RD, The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. Eur J Nucl Med Mol Imaging 2003;30:423-6
   PubMed Web of Science ®Google Scholar
• Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88
   PubMed Web of Science ®Google Scholar
• Modi NB, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 2000;40:1141-9
   PubMed Web of Science ®Google Scholar
• Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000;21:23-31
   PubMed Web of Science ®Google Scholar
• Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med. Res Opin 2002;18:311-16
   PubMed Web of Science ®Google Scholar
• Adler LA, Zimmerman B, Starr HL, Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009;29:239-47
   PubMed Web of Science ®Google Scholar
• Medori R, Ramos-Quiroga JA, Casas M, A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-9
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007;47:1476-88
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007;27:459-67
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Ciccone PE, PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
   PubMed Web of Science ®Google Scholar
• Cox DJ, Merkel RL, Penberthy JK, Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 2004;43:269-75
   PubMed Web of Science ®Google Scholar
• Cox DJ, Humphrey JW, Merkel RL, Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 2004;17:235-9
   PubMedGoogle Scholar
• Cox DJ, Merkel RL, Moore M, Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 2006;118:e704-10
   PubMed Web of Science ®Google Scholar
• Chronis-Tuscano A, Seymour KE, Stein MA, Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry 2008;69:1938-47
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Williams ED, Strong RE, A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007;68:93-101
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X, Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-11
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Mick E, Surman CB, A randomized, single-blind, substitution study of OROS methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord 21 May 2010. [Epub ahead of print]
   Google Scholar
• Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-91
   PubMed Web of Science ®Google Scholar
• Biederman J, Monuteaux MC, Spencer T, Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165:597-603
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adamson J, Monuteaux MC, Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008;162:916-21
   PubMed Web of Science ®Google Scholar
• Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85
   PubMed Web of Science ®Google Scholar
• Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010;108:130-3
   PubMed Web of Science ®Google Scholar
• Diller L. ADHD in the college student: is anyone else worried? J Atten Disord 2010;14:3-6
   PubMedGoogle Scholar
• Safren SA, Sprich SE, Cooper-Vince C, Life impairments in adults with medication-treated ADHD. J Atten Disord 2010;13:524-31
   PubMedGoogle Scholar
• Spencer TJ, Adler LA, Meihua Q, Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord 2010;14:57-68
   PubMed Web of Science ®Google Scholar
• Barkley RA, Murphy KR, Fischer M. ADHD in adults: what the science says. 1st edition. Guilford Press, New York; 2007
   Google Scholar